ENSAYOS CLÍNICOS TUMORES DIGESTIVO

- COLORRECTAL

**SMS-0472B**

“A randomized, multicentre, open-label controlled phase II trial of Foxy-5 as neo-adjuvant therapy in subjects with Wnt-5a negative colon cancer”

[https://clinicaltrials.gov/ct2/show/NCT03883802](https://clinicaltrials.gov/ct2/show/NCT03883802)

**BNT 122-01**

“A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II(high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection.”

[https://clinicaltrials.gov/ct2/show/NCT04486378](https://clinicaltrials.gov/ct2/show/NCT04486378)

**SEQUENCE (TTD-18-01)**

“Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CR-SEQUENCE”

[https://clinicaltrials.gov/ct2/show/NCT03635021](https://clinicaltrials.gov/ct2/show/NCT03635021)

**G1T28-207 (PRESERVE)**

“A phase III study Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer.”

[https://clinicaltrials.gov/ct2/show/NCT04607668](https://clinicaltrials.gov/ct2/show/NCT04607668)

**MK7339-003**

“A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With S-FU in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)”

[https://clinicaltrials.gov/ct2/show/NCT04456699](https://clinicaltrials.gov/ct2/show/NCT04456699)

**CA209-9N9**

“A Study Of Nivolumab In Combination With Trametinib With Or Without Iplimumab In Participants With Previously Treated Metastatic Colorectal Cancers”

**ACT16902-S04**

“A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with advanced and metastatic gastrointestinal cancer (Pegasus Gastrointestinal 203)"

[https://clinicaltrials.gov/ct2/show/NCT05104567](https://clinicaltrials.gov/ct2/show/NCT05104567)

**MK1308A-008**

“A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)”

[https://clinicaltrials.gov/ct2/show/NCT04895722](https://clinicaltrials.gov/ct2/show/NCT04895722)

**GÁSTRICO**

**MATTERHORN (D910GC00001)**

“A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)”

[https://clinicaltrials.gov/ct2/show/NCT04592913](https://clinicaltrials.gov/ct2/show/NCT04592913)

**SPOTLIGHT**

“A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2- Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma”

[https://clinicaltrials.gov/ct2/show/NCT03504397](https://clinicaltrials.gov/ct2/show/NCT03504397)

**MK-7902-015**

“Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy Compared With Standard of Care Therapy as First-line Intervention in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)”

[https://clinicaltrials.gov/ct2/show/NCT04662710](https://clinicaltrials.gov/ct2/show/NCT04662710)

**DS8201-A-U306**

“A PHASE 3, MULTICENTER, 2-ARM RANDOMIZED, OPEN-LABEL STUDY OF TRASTUZUMAB DERUXTECAN IN SUBJECTS WITH HER2-POSITIVE METASTATIC AND/OR UNRESECTABLE GASTRIC OR GASTRO-ESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PROGRESSED ON OR AFTER A TRASTUZUMAB-CONTAINING REGIMEN (DESTINY-GASTRIC04)”
**KUNLUN—D910SC00001**

“A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)”

https://clinicaltrials.gov/ct2/show/NCT04550260

**CS1003—305**

“A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)”

https://clinicaltrials.gov/ct2/show/NCT04194775

**INCB 54828-302**

“A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement”.

https://clinicaltrials.gov/ct2/show/NCT03656536

**NUCANA NUTIDE**

“A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer”

https://clinicaltrials.gov/ct2/show/NCT04163900

**QBGJ398—301**

“A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial”

https://clinicaltrials.gov/ct2/show/NCT03773302
**TAS-120-301**

“A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements”  
https://clinicaltrials.gov/ct2/show/NCT04093362

**DZB-CS-301**

“Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)“  
https://clinicaltrials.gov/ct2/show/NCT03230318

**ZWI-ZW25-203**

“A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.”  
https://clinicaltrials.gov/ct2/show/NCT04466891

**- NEUROENDOCRINO**

**NETTER**

“A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET”  
https://clinicaltrials.gov/ct2/show/NCT03972488

**- PÁNCREAS**

**CNIS793B12301**

“A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nabpaclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)”.  
https://clinicaltrials.gov/ct2/show/NCT04935359